{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:05:52Z","timestamp":1788973552603,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier","isbn-type":[{"value":"9780128154168","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.irn.2018.07.025","type":"book-chapter","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T22:56:58Z","timestamp":1533250618000},"page":"443-462","source":"Crossref","is-referenced-by-count":25,"title":["Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature"],"prefix":"10.1016","author":[{"given":"Panagiotis","family":"Zis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos-Dimitrios","family":"Mitsikostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2018.07.025_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-018-0947-3","article-title":"Sensory neuropathic symptoms in idiopathic Parkinson's disease: Prevalence and impact on quality of life","author":"Adewusi","year":"2018","journal-title":"Acta Neurologica Belgica"},{"key":"10.1016\/bs.irn.2018.07.025_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2018.06.022","article-title":"Peripheral neuropathic pain in idiopathic Parkinson's disease: Prevalence and impact on quality of life; a case controlled study","volume":"392","author":"Adewusi","year":"2018","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2018.07.025_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijpsycho.2016.08.009","article-title":"Expectation of nocebo hyperalgesia affects EEG alpha-activity","volume":"109","author":"Albu","year":"2016","journal-title":"International Journal of Psychophysiology"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pain.2009.07.010","article-title":"A systematic review of adverse events in placebo groups of anti-migraine clinical trials","volume":"146","author":"Amanzio","year":"2009","journal-title":"Pain"},{"issue":"8","key":"10.1016\/bs.irn.2018.07.025_bb0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.12998\/wjcc.v3.i8.682","article-title":"Depressive symptoms in neurodegenerative diseases","volume":"3","author":"Baquero","year":"2015","journal-title":"World Journal of Clinical Cases"},{"issue":"5","key":"10.1016\/bs.irn.2018.07.025_bb0035","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"10.1016\/bs.irn.2018.07.025_bb0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S1474-4422(16)00066-1","article-title":"Increasing uncertainty in CNS clinical trials: The role of placebo, nocebo, and Hawthorne effects","volume":"15","author":"Benedetti","year":"2016","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2018.07.025_bb0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","article-title":"When words are painful: Unraveling the mechanisms of the nocebo effect","volume":"147","author":"Benedetti","year":"2007","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000000585","article-title":"Nocebo and pain: An overview of the psychoneurobiological mechanisms","volume":"2","author":"Blasini","year":"2017","journal-title":"Pain Reports"},{"key":"10.1016\/bs.irn.2018.07.025_bb0055","doi-asserted-by":"crossref","first-page":"b158","DOI":"10.1136\/bmj.b158","article-title":"Alzheimer's disease","volume":"338","author":"Burns","year":"2009","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1016\/bs.irn.2018.07.025_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plastic and Reconstructive Surgery"},{"issue":"6359","key":"10.1016\/bs.irn.2018.07.025_bb0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.aap8488","article-title":"Nocebo effects can make you feel pain","volume":"358","author":"Colloca","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.irn.2018.07.025_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/15265161.2017.1314057","article-title":"Tell me the truth and I will not be harmed: Informed consents and nocebo effects","volume":"17","author":"Colloca","year":"2017","journal-title":"The American Journal of Bioethics"},{"issue":"6","key":"10.1016\/bs.irn.2018.07.025_bb0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11916-014-0419-2","article-title":"Understanding placebo and nocebo responses for pain management","volume":"18","author":"Colloca","year":"2014","journal-title":"Current Pain and Headache Reports"},{"issue":"7","key":"10.1016\/bs.irn.2018.07.025_bb0080","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosomatic Medicine"},{"issue":"9648","key":"10.1016\/bs.irn.2018.07.025_bb0085","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"72","author":"Compston","year":"2008","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1212\/01.WNL.0000078887.16593.12","article-title":"Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome","volume":"61","author":"Connor","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2018.07.025_bb0095","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/MAO.0000000000001555","article-title":"Nocebo effect in Meniere's disease: A meta-analysis of placebo-controlled randomized controlled trials","volume":"38","author":"Dimitriadis","year":"2017","journal-title":"Otology and Neurotology"},{"issue":"6","key":"10.1016\/bs.irn.2018.07.025_bb0100","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4088\/JCP.13r08858","article-title":"Nocebo effects in the treatment of major depression: Results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials","volume":"76","author":"Dodd","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1016\/bs.irn.2018.07.025_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2012.01950.x","article-title":"How positive and negative expectations shape the experience of visceral pain: An experimental pilot study in healthy women","volume":"24","author":"Elsenbruch","year":"2012","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/bs.irn.2018.07.025_bb0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","article-title":"New insights into the placebo and nocebo responses","volume":"59","author":"Enck","year":"2008","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/bs.irn.2018.07.025_bb0115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015","volume":"16","year":"2017","journal-title":"The Lancet. Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2018.07.025_bb0120","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1073\/pnas.071582498","article-title":"Mechanisms of migraine aura revealed by functional MRI in human visual cortex","volume":"98","author":"Hadjikhani","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.irn.2018.07.025_bb0125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/AJP.0b013e3182321ad8","article-title":"Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: Systematic review","volume":"28","author":"H\u00e4user","year":"2012","journal-title":"Clinical Journal of Pain"},{"issue":"9996","key":"10.1016\/bs.irn.2018.07.025_bb0130","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/bs.irn.2018.07.025_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081878","article-title":"Expectation modulates the effect of deep brain stimulation on motor and cognitive function in tremor-dominant Parkinson's disease","volume":"8","author":"Keitel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2018.07.025_bb0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbr.2013.04.051","article-title":"Motor and cognitive placebo-\/nocebo-responses in Parkinson's disease patients with deep brain stimulation","volume":"250","author":"Keitel","year":"2013","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1385\/JMN:17:2:225","article-title":"Lewy body pathology in Alzheimer's disease","volume":"17","author":"Kotzbauer","year":"2001","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/bs.irn.2018.07.025_bb0150","article-title":"Great expectations: The placebo effect in Parkinson's disease","volume":"Vol. 225","author":"Lidstone","year":"2014"},{"issue":"4","key":"10.1016\/bs.irn.2018.07.025_bb0155","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0160","first-page":"E157","article-title":"Placebo and nocebo in interventional pain management: A friend or a foe\u2014Or simply foes?","volume":"14","author":"Manchikanti","year":"2011","journal-title":"Pain Physician"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0165","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/mds.26500","article-title":"Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects","volume":"31","author":"Mestre","year":"2016","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11910-011-0245-4","article-title":"Nocebo in headaches: Implications for clinical practice and trial design","volume":"12","author":"Mitsikostas","year":"2012","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1016\/bs.irn.2018.07.025_bb0175","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2011.03528.x","article-title":"Nocebo in fibromyalgia: Meta-analysis of placebo-controlled clinical trials and implications for practice","volume":"19","author":"Mitsikostas","year":"2012","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10072-014-1959-2","article-title":"Q-No: A questionnaire to predict nocebo in outpatients seeking neurological consultation","volume":"36","author":"Mitsikostas","year":"2015","journal-title":"Neurological Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2018.07.025_bb0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0333102410391485","article-title":"Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches","volume":"31","author":"Mitsikostas","year":"2011","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/bs.irn.2018.07.025_bb0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.psychres.2013.10.019","article-title":"Nocebo in clinical trials for depression: A meta-analysis","volume":"215","author":"Mitsikostas","year":"2014","journal-title":"Psychiatry Research"},{"key":"10.1016\/bs.irn.2018.07.025_bb0195","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"9971","key":"10.1016\/bs.irn.2018.07.025_bb0200","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: New advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/bs.irn.2018.07.025_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-011-8287-6","article-title":"Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy","volume":"42","author":"Nakahara","year":"2012","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"7","key":"10.1016\/bs.irn.2018.07.025_bb0210","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1352458510370793","article-title":"Nocebo effects in multiple sclerosis trials: A meta-analysis","volume":"16","author":"Papadopoulos","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0215","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00415-011-6197-4","article-title":"A meta-analytic approach to estimating nocebo effects in neuropathic pain trials","volume":"259","author":"Papadopoulos","year":"2012","journal-title":"Journal of Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2018.07.025_bb0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.13m08797","article-title":"The role of patient expectancy in placebo and nocebo effects in antidepressant trials","volume":"75","author":"Rutherford","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2018.07.025_bb0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11682-017-9675-1","article-title":"Emotion-specific nocebo effects: An fMRI study","volume":"12","author":"Schienle","year":"2018","journal-title":"Brain Imaging and Behavior"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0230","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2007.34","article-title":"Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses","volume":"65","author":"Scott","year":"2008","journal-title":"Archives of General Psychiatry"},{"issue":"7\u20138","key":"10.1016\/bs.irn.2018.07.025_bb0235","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/21678421.2017.1335325","article-title":"Nocebo in motor neuron disease: Systematic review and meta-analysis of placebo-controlled clinical trials","volume":"18","author":"Shafiq","year":"2017","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"issue":"23","key":"10.1016\/bs.irn.2018.07.025_bb0240","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1212\/WNL.0000000000004004","article-title":"Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis","volume":"88","author":"Silva","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0245","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.12014","article-title":"Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: A meta-analysis","volume":"20","author":"Stathis","year":"2013","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2018.07.025_bb0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","article-title":"Migraine is first cause of disability in under 50s: Will health politicians now take notice?","volume":"19","author":"Steiner","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/bs.irn.2018.07.025_bb0255","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"The Parkinson Study Group","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.irn.2018.07.025_bb0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(05)70139-3","article-title":"The restless legs syndrome","volume":"4","author":"Trenkwalder","year":"2005","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2018.07.025_bb0265","series-title":"International classification of diseases, 10th revision (ICD-10)","author":"World Health Organization","year":"1992"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0270","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00415-014-7391-y","article-title":"Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: A systematic review","volume":"262","author":"Zaccara","year":"2015","journal-title":"Journal of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.07.025_bb0275","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00415-015-8018-7","article-title":"Analysis of nocebo effects of antiepileptic drugs across different conditions","volume":"263","author":"Zaccara","year":"2016","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2018.07.025_bb0280","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2147\/CIA.S113576","article-title":"Depression and chronic pain in the elderly: Links and management challenges","volume":"12","author":"Zis","year":"2017","journal-title":"Clinical Interventions in Aging"},{"issue":"2","key":"10.1016\/bs.irn.2018.07.025_bb0285","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-2012-120073","article-title":"Oxidative stress and memory decline in adults with Down syndrome: Longitudinal study","volume":"31","author":"Zis","year":"2012","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2018.07.025_bb0290","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/npjparkd.2015.13","article-title":"The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: A state-of-the-art systematic review","volume":"1","author":"Zis","year":"2015","journal-title":"NPJ Parkinson's Disease"},{"key":"10.1016\/bs.irn.2018.07.025_bb0295","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jns.2017.05.023","article-title":"Peripheral neuropathy in idiopathic Parkinson's disease: A systematic review","volume":"378","author":"Zis","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"issue":"388","key":"10.1016\/bs.irn.2018.07.025_bb0300","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jns.2018.03.009","article-title":"Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials","volume":"15","author":"Zis","year":"2018","journal-title":"Journal of the Neurological Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2018.07.025_bb0305","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/ene.12733","article-title":"Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: Argument for non-motor subtypes","volume":"22","author":"Zis","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.07.025_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097709","article-title":"Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress","volume":"9","author":"Zis","year":"2014","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.07.025_bb0315","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jns.2015.05.029","article-title":"Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials","volume":"355","author":"Zis","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2018.07.025_bb0320","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JPD-140372","article-title":"Non-motor symptoms profile and burden in drug na\u00efve versus long-term Parkinson's disease patients","volume":"4","author":"Zis","year":"2014","journal-title":"Journal of Parkinson's Disease"},{"key":"10.1016\/bs.irn.2018.07.025_bb0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.seizure.2016.12.003","article-title":"Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials","volume":"45","author":"Zis","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/bs.irn.2018.07.025_bb0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2017.08.024","article-title":"Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome","volume":"114","author":"Zis","year":"2018","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/bs.irn.2018.07.025_bb0335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neulet.2016.11.023","article-title":"Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity","volume":"636","author":"Zis","year":"2017","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2018.07.025_bb0340","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1523\/JNEUROSCI.5140-05.2006","article-title":"Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism","volume":"26","author":"Heimer","year":"2006","journal-title":"The Journal of Neuroscience"}],"container-title":["International Review of Neurobiology","Neurobiology of the Placebo Effect Part II"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T06:25:30Z","timestamp":1604730330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774218300540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128154168"],"references-count":67,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2018.07.025","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}